Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

(Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

GSK, a prominent player in the pharmaceuticals sector, and Renishaw, an industrial technology firm within,Growth stock,, recently provided significant updates on their respective operations. GSK ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...